CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian...
Phase 3
Roma, Italy and 179 other locations
followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...
Phase 3
Roma, Italy and 213 other locations
of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...
Phase 3
Roma, Italy and 126 other locations
of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...
Phase 3
Roma, RM, Italy and 92 other locations
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....
Phase 3
Roma, Italy and 176 other locations
(PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing hig...
Phase 3
Roma, Italy and 124 other locations
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...
Phase 3
Roma, Italy and 105 other locations
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer....
Phase 2
Rome, Rome, Italy and 65 other locations
with either niraparib or lartesertib in participants with epithelial ovarian cancer and to assess any differences between tuvuserti...
Phase 2
Rome, Italy and 83 other locations
of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus* The study wil...
Phase 1, Phase 2
Rome, Lazio, Italy and 52 other locations
Clinical trials
Research sites
Resources
Legal